Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10377737" target="_blank" >RIV/00216208:11140/18:10377737 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/18:10377737

Výsledek na webu

<a href="https://doi.org/10.1097/MEG.0000000000001084" target="_blank" >https://doi.org/10.1097/MEG.0000000000001084</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MEG.0000000000001084" target="_blank" >10.1097/MEG.0000000000001084</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease

Popis výsledku v původním jazyce

BackgroundThere is lack of evidence to guide the type, intensity, and the duration of anticoagulation following venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD).Patients and methodsRegistro Informatizado Enfermedad Trombo Embolica (RIETE) is an ongoing, multicenter, observational registry of consecutive patients with symptomatic, objectively confirmed, acute VTE. We used the RIETE database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in noncancer patients with or without IBD.ResultsAs of October 2014, 41927 patients without active cancer have been recruited in RIETE. Of these, 265 (0.63%) had IBD and 85 (32%) had the VTE during an acute flare. The duration of anticoagulation was similar in patients with VTE during an acute flare (8.38.8 months), in remission (9.4 +/- 11.5 months), or without IBD (10.0 +/- 12.8 months). The rate of VTE recurrences [7.25, 95% confidence interval (CI): 1.46-21.2; 8.84, 95% CI: 3.23-19.2; and 5.85, 95% CI: 5.46-6.26 per 100 patient-years, respectively] and major bleeding (7.25, 95% CI: 1.46-21.2; 2.95, 95% CI: 0.33-10.6; and 4.79, 95% CI: 4.44-5.15, respectively) were similar in all three subgroups. Propensity score matching analysis confirmed the absence of differences in the rate of VTE recurrences (rate ratio: 1.16, 95% CI: 0.54-2.47) or major bleeding (rate ratio: 0.84, 95% CI: 0.31-2.23) between patients with or without IBD.ConclusionTherapeutic anticoagulation for patients with IBD and VTE is as safe and effective as for those with VTE without IBD.

Název v anglickém jazyce

Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease

Popis výsledku anglicky

BackgroundThere is lack of evidence to guide the type, intensity, and the duration of anticoagulation following venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD).Patients and methodsRegistro Informatizado Enfermedad Trombo Embolica (RIETE) is an ongoing, multicenter, observational registry of consecutive patients with symptomatic, objectively confirmed, acute VTE. We used the RIETE database to compare the rate of VTE recurrences and major bleeding during the course of anticoagulation in noncancer patients with or without IBD.ResultsAs of October 2014, 41927 patients without active cancer have been recruited in RIETE. Of these, 265 (0.63%) had IBD and 85 (32%) had the VTE during an acute flare. The duration of anticoagulation was similar in patients with VTE during an acute flare (8.38.8 months), in remission (9.4 +/- 11.5 months), or without IBD (10.0 +/- 12.8 months). The rate of VTE recurrences [7.25, 95% confidence interval (CI): 1.46-21.2; 8.84, 95% CI: 3.23-19.2; and 5.85, 95% CI: 5.46-6.26 per 100 patient-years, respectively] and major bleeding (7.25, 95% CI: 1.46-21.2; 2.95, 95% CI: 0.33-10.6; and 4.79, 95% CI: 4.44-5.15, respectively) were similar in all three subgroups. Propensity score matching analysis confirmed the absence of differences in the rate of VTE recurrences (rate ratio: 1.16, 95% CI: 0.54-2.47) or major bleeding (rate ratio: 0.84, 95% CI: 0.31-2.23) between patients with or without IBD.ConclusionTherapeutic anticoagulation for patients with IBD and VTE is as safe and effective as for those with VTE without IBD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Gastroenterology &amp; Hepatology

ISSN

0954-691X

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

526-530

Kód UT WoS článku

000429013300005

EID výsledku v databázi Scopus

2-s2.0-85044954004